ZLNA ZELLUNA ASA

Zelluna ASA: Disclosure of large shareholding

Zelluna ASA: Disclosure of large shareholding

Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the "Private Placement"), divided on a first tranche of 3,729,774 new shares and a second tranche of 1,770,226 new shares ("Tranche 2"), and the allocation of 315,639 new shares in a retail offering via the PrimaryBid Platform. 

Radforsk Investeringsstiftelse ("Radforsk") holds 2,469,693 shares in the Company, currently representing 10.08% of the total number of shares and votes in the Company.

The issuance of the 1,770,226 new shares in Tranche 2 of the Private Placement was approved by the extraordinary general meeting of the Company held on 25 November 2025. Following registration of the share capital increase pertaining to the issuance of the new shares in Tranche 2 with the Norwegian Register of Business Enterprises, the shareholding of Radforsk will, as a result of the dilutive effect of such share capital increase, cross below the 10% threshold pursuant to section 4-2 of the Norwegian Securities Trading Act. The shareholding of Radforsk will at such time continue to be 2,469,693 shares, which after registration of the share capital increase will be equal to 9.40% of the shares and votes in the Company.

This disclosure is made pursuant to Section 4-2 of the Norwegian Securities Trading Act.



EN
27/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZELLUNA ASA

 PRESS RELEASE

Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 Firs...

Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial Regulatory clearance enables start of clinical testing and marks transition to clinical-stage companyOn track for initial clinical data to emerge from mid-2026 Oslo, Norway, 20 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) has approved the Comp...

 PRESS RELEASE

Zelluna mottar UK MHRA og etisk godkjenning for oppstart av ZIMA-101 f...

Zelluna mottar UK MHRA og etisk godkjenning for oppstart av ZIMA-101 første-i-menneske klinisk studie Regulatorisk godkjenning muliggjør oppstart av klinisk testing og markerer overgang til klinisk faseFørste kliniske data forventes fra medio 2026 Oslo, Norge, 20 februar 2026 – Zelluna (OSE: ZLNA) utvikler allogene "off-the-shelf" T-cellereseptor-baserte naturlige dreperceller (TCR-NK) for behandling av solide kreftformer. Selskapet kunngjør i dag at Medicines and Healthcare products Regulatory Agency (MHRA) og Research Ethics Committee (REC) i Storbritannia har godkjent selskapets søkna...

 PRESS RELEASE

Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved w...

Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved with CTA Submission Oslo, 12 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents its results for the fourth quarter and full year 2025. Webcast scheduled for 12 February 2026, at 08:30 (CET). Link to webcast . Operational Highlights Q4 2025 CTA submitted: On 17 December 2025, Zelluna submitted its first Clinical Trial Application (CTA) to the UK MHRA for ZI-MA4-1, the world's ...

 PRESS RELEASE

Zelluna ASA: Fjerde kvartal 2025 – Viktig regulatorisk milepæl oppnådd...

Zelluna ASA: Fjerde kvartal 2025 – Viktig regulatorisk milepæl oppnådd med CTA-innlevering Oslo, 12. februar 2026 – Zelluna (OSE: ZLNA), et selskap som utvikler allogene "off-the-shelf" T-cellereseptor-baserte Natural Killer (TCR-NK) celleterapier for behandling av kreft, presenterer i dag resultatene for fjerde kvartal og året 2025. Webcast er planlagt 12. februar 2026 kl. 08:30 (CET). Lenke til webcast . Operasjonelle høydepunkter Q4 2025: CTA innlevert: 17. desember 2025 leverte Zelluna sin første søknad om oppstart av klinisk studie (Clinical Trial Application, CTA) til UK MH...

 PRESS RELEASE

Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical tr...

Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial Global CRO to support execution of ZIMA-101 study with world's first MAGE-A4-targeting TCR-NK cell therapy productPartnership follows submission of the Clinical Trial Application (CTA) to the MHRA Oslo, Norway – 11 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced a clinical partnership with Medpace, a leading global Contract Research Organization (CRO), to support the f...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch